Office based transurethral needle ablation of the prostate with analgesia and local anesthesia.
OBJECTIVE
We evaluated the efficacy and feasibility of performing office based transurethral needle ablation of the prostate with analgesia and local anesthesia.


METHODS
A total of 56 consecutive patients underwent transurethral needle ablation of the prostate for symptomatic benign prostatic hyperplasia. Oral rofecoxib (50 mg) and ciprofloxacin (250 mg) were administered before the procedure with 25 mg hydroxyzine and 50 to 100 mg meperidine intramuscularly. A combination of 2% lidocaine solution and jelly was used for anesthesia. Patients rated discomfort during anesthesia administration and the procedure using a 10-point scale of 0--no discomfort to 10--the worst pain/discomfort ever experienced in the patient life. Overall satisfaction with the procedure was assessed with a 4-point scale of 1--very satisfactory to 4--very unsatisfactory. Followup was 12 months for uroflow and 36 months for International Prostate Symptom Score.


RESULTS
The mean age of 47 patients was 65.4 years. Mean discomfort ratings were 3.6 and 4.9 for anesthesia administration and the procedure, respectively. Average operative time was 34.4 minutes, excluding anesthesia administration. The mean overall satisfaction score was 1.5. The mean preoperative International Prostate Symptom Score was 23.1, which improved to 10.9, 11.2, 12.3, 13.8 and 11.3 at 3, 6, 12, 24 and 36 months, respectively. Mean maximum uroflow improved from 8.2 ml/sec at baseline to 12.8, 13.9 and 13.3 ml/sec at 3, 6 and 12 months, respectively.


CONCLUSIONS
Administration of an intramuscular narcotic combined with oral analgesic and topical lidocaine provided adequate pain control for transurethral needle ablation of the prostate, making it a feasible office procedure.
Leocádio
Dean E
DE
Department of Urology Rhode Island Hospital, Providence, Rhode Island 02905, USA.
Frenkl
Tara L
TL
Stein
Barry S
BS
D000293:Adolescent; D000328:Adult; D000556:Ambulatory Surgical Procedures / Q000379:methods*; D000698:Analgesia / Q000379:methods*; D000701:Analgesics, Opioid / Q000008:administration & dosage; D000772:Anesthesia, Local / Q000379:methods*; D000779:Anesthetics, Local / Q000008:administration & dosage; D017115:Catheter Ablation / Q000295:instrumentation*; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D004867:Equipment Design; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D008614:Meperidine / Q000008:administration & dosage; D008875:Middle Aged; D009339:Needles; D010147:Pain Measurement; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000503:physiopathology / Q000601:surgery*; D020728:Transurethral Resection of Prostate / Q000379:methods*; D016896:Treatment Outcome; D014563:Urodynamics
D000701:Analgesics, Opioid; D000779:Anesthetics, Local; D008012:Lidocaine; D008614:Meperidine